Please assess the completion status of the following clinical trial:

Trial Title: Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 20 to ≤75 years old~* Patient with essential hypertension~Exclusion Criteria:~* When the BP level measured at screening was sitDBP\>120 mmHg or sitSBP \>180 mmHg~* Patient with difference in repeatedly measured blood pressures from the selected arm at screening was sitSBP≥ 20mmHg or sitDBP ≥ 10mmHg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lercanidipine 10mg (Type: ACTIVE_COMPARATOR): 1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
- Lercanidipine10mg /Valsartan 80mg (Type: EXPERIMENTAL): 1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
- Lercanidipine 10mg /Valsartan 160mg (Type: EXPERIMENTAL): 1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)

Based on this trial design, predict the completion outcome and termination type (if applicable).